Understanding the Role of Bispecific Antibodies in the Management of B-Cell Non-Hodgkin Lymphoma: A New Immunotherapy That Is Here to Stay

• DOI: 10.3390/lymphatics1030015
• Publication Date: 2023-10-09T11:37:50Z
• Authors: Stanislav Ivanov; Meri Muminovic; Jose Sandoval-Sus
• Keywords: Refractory (planetary science)

Non-Hodgkin lymphomas (NHLs) represent a diverse group of hematologic malignancies derived from various cells. B-cell NHLs the largest fraction diagnosed and treated in United States. Standard chemo-immunotherapies with rituximab multiagent cytotoxic regimens have proven to be effective management these lymphoproliferative neoplasms; nonetheless, considerable patients still experience relapse or treatment-refractory disease. Therapeutic advances using novel immunotherapeutic agents as well cell-based treatments, such chimeric antigen receptor (CAR) T-cell therapies, improved outcomes relapsed/refractory (R/R) NHL. Most new treatment strategies are not curative most succumb R/R disease, leaving this population an unmet need for well-tolerated therapeutic options. One up-and-coming options bispecific antibodies (BsAb), either single agent combination other medications. Conclusion: BsAbs offer “off shelf” chemotherapy-free approach Advancements antibody construct design along safety profile clinical effectiveness recent suggest that promising option